Patent classifications
C07D473/18
Conformationally-preorganized, miniPEG-containing γ-peptide nucleic acids
The present invention relates to -PNA monomers according to Formula I where substituent groups R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, B and P are defined as set forth in the specification. The invention also provides methodology for synthesizing compounds according to Formula I and methodology for synthesizing PNA oligomers that incorporate one or more Formula I monomers.
TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A PYRIDINE OR PYRAZINE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
Compounds having a structure according to formula (I)
##STR00001##
where R.sup.1 and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A PYRIDINE OR PYRAZINE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
Compounds having a structure according to formula (I)
##STR00001##
where R.sup.1 and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A BENZOTRIAZOLE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
Compounds having a structure according to formula (I)
##STR00001##
where R.sup.1, R.sup.2, and R.sup.3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A BENZOTRIAZOLE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
Compounds having a structure according to formula (I)
##STR00001##
where R.sup.1, R.sup.2, and R.sup.3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
METHOD OF TREATING MICROBIAL INFECTIONS
The disclosure provides for novel antimicrobial agents, methods of making, and methods of use thereof.
METHOD OF TREATING MICROBIAL INFECTIONS
The disclosure provides for novel antimicrobial agents, methods of making, and methods of use thereof.
Guanine Analogs as Telomerase Substrates and Telomere Length Affectors
This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
Guanine Analogs as Telomerase Substrates and Telomere Length Affectors
This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
Compounds having a structure according to formula (I) or (II)
##STR00001##
where R.sup.1, R.sup.2, R.sup.3, R.sup.4, Ar and X.sup.1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.